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assessed survival in patients subdivided according to hematocrit
values 35%, 35% to 39%, and 40%. It is not clear why the
investigators grouped all patients with a hematocrit value of 40%
(n  5,128, 77%) into one category. According to data from
Europe and North America, the normal range of hematocrit for
males is 40% to 53% and that of females 36% to 48% (5). Therefore,
it would have been more appropriate to further subdivide patients
with a hematocrit above 40%, enabling the impact of polycythemia on
survival to be assessed. Heart failure is a procoagulant state, even for
patients in sinus rhythm, and hence polycythemic patients are likely to
be at particular risk of thrombotic events and would be expected to
have a higher mortality.
In vitro studies have shown that angiotensin-converting enzyme
inhibitors can lower hematocrit levels via the inhibition of eryth-
ropoietin synthesis. It would have been interesting to have assessed
whether enalapril treatment resulted in a clinically significant
change in hematocrit over time. Although Al-Ahmad et al.
excluded patients with severe pulmonary disease from their study,
whether patients with coexisting chronic obstructive pulmonary
disease (COPD) were also excluded is not reported. This may be
an important confounding factor as COPD is a well-recognized
cause of secondary polycythemia.
The study by Al-Ahmad and colleagues (1) mostly investigated
male (86%) and asymptomatic (62%) patients. The use of eryth-
ropoietin for the treatment of anemia in CHF is likely to benefit
only symptomatic patients, particularly those with more advanced
heart failure. Although the findings of Al-Ahmad et al. are clearly
of significance, further studies are required to establish which
patients should be targeted for erythropoietin therapy and whether
there is an optimal range of hematocrit (or hemoglobin) for which
one should aim.
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REPLY
Dr. Sharma and colleagues raise the question of a U-shaped
relationship between hematocrit and all-cause mortality. We
explored the possibility of a nonlinear relationship between hemat-
ocrit and survival time by including a quadratic hematocrit term in
the Cox regression (1). The term was not significant, which
allowed us to rule out a simple U relationship. We did not present
analyses of all-cause mortality itself because follow-up times were
quite variable and much of the data was censored. However, as an
example of these results, in our data those male patients with
hematocrit from 40% to 49% (n  4,235) had 22% mortality,
whereas those male patients with hematocrit of 50 or higher (n 
344) had a mortality of 23%, not a statistically significant difference
(p  0.47). We concluded that a nonlinear model did not fit the
data any better than did a linear model.
Sharma and colleagues also question our subdivision of the
population into hematocrit values 35, 35 to 39, and 40%. The
division into subgroups was performed both to describe the
prevalence of risk factors as hematocrit declines into the anemic range
and to provide a graphic representation of the effect of a decline in
hematocrit into the anemic range using univariate Kaplan-Meier
analyses. In the multivariable Cox proportional hazards model, how-
ever, hematocrit was evaluated as a continuous variable.
We agree that additional randomized controlled trials are
needed to assess the efficacy, safety, and potential target hematocrit
(hemoglobin) goals in patients with heart failure. Silverberg et al.
(2) did not note any adverse side effects in patients with advanced
heart failure who were randomized to a treatment hemoglobin goal
of at least 12.5 g/dl compared with the placebo arm of 10 to
11.5 g/dl. However, a recent randomized controlled trial in the
hemodialysis population, in patients with a history of heart failure
or ischemic heart disease, showed a trend toward worse outcomes
in those patients whose goal hematocrit was 42% compared with
those whose goal was 30% (3). Admittedly, dialysis patients are
distinct from heart failure patients in the general population;
however, caution should be exercised when choosing the higher
hematocrit target in clinical trials of patients with heart failure.
Sharma et al. make the point that in vitro studies show that
angiotensin-converting enzyme inhibitors (ACE-I) may lower the
hematocrit. In fact, human studies using ACE-I have shown
similar results (4,5). Analyses of follow-up of hematocrit levels may
have been insightful, but we believed this was beyond the scope
and goal of the current study.
Finally, Sharma and co-workers are of the opinion that treat-
ment of anemia is likely to benefit only symptomatic patients.
Although this may be true, we believe this conclusion is premature. In
fact, although we did not show the analyses in our report, the hazard
ratio for every decrease in unit hematocrit was similar in the asymp-
tomatic prevention and the symptomatic treatment trials of the
Studies of Left Ventricular Dysfunction, implying that treatment of
anemia could theoretically be useful even in asymptomatic patients.
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Complications of Vascular
Closure Devices—Not Yet Evidence Based
The interesting publication by Dangas et al. (1) claims to compare
arteriotomy closure devices with manual compression after percu-
taneous coronary intervention. Unfortunately, this is a comparison
only in the fashion that can be ascribed to a retrospective trial with
mismatched procedural variables and operator experience, ad hoc
recruitment, and broadly applied statistical techniques. The con-
clusion that closure devices are associated with a higher rate of
vascular complications could not possibly be ascertained from this
study. In fairness to the investigators, the segment of the inter-
ventional cardiology literature to which they have contributed is
largely a collection of testimonials and historical comparisons (2).
Unfortunately, there is a striking paucity of properly conducted
controlled clinical trials in this arena.
Our problems with this study (1) are multiple, some of which were
outlined in the accompanying editorial by Tavris et al. (3). First, the
investigators claim that “no large report exists on the ‘real world’
application” of these devices. Multiple studies have reported far larger
experiences, at least as “real world” as the investigators’ (4–6).
Second, Dangas et al., highly experienced and with an interna-
tional reputation in interventional cardiology, are largely novices at
vascular closure, having apparently declined to adopt them in
routine use. They include experience with only 6 Vasoseals, 32 Duetts,
and 6 Prostars; the majority of cases used Angioseals and Techstars.
The 516 deployments constitute only 8% of their cases, and amounts
to fewer than 150 cases per year, spread over multiple operators. In
contrast, the learning curve for one Perclose device as published by
Balzer et al. (6) appears to level off at approximately 350 cases.
Third, the individual operators may not have used the recom-
mended techniques for device deployment. For example, even
though femoral artery angiography “was recommended before
arteriotomy closure device application,” it was used only “in the
majority of cases” (we are not told the actual number). This is
clearly a disadvantage and probably inappropriate handling of the
devices, as numerous factors that predict outcome and might
demonstrate contraindications to device deployment were unknown
to the operators in what is likely a high percentage of the cases. Also,
because at least 13% and probably more of these femoral sticks were
not in the common femoral artery (regardless of the operators being
“very experienced with arterial puncture”), any number of the
pseudoaneurysms and retroperiotoneal bleeds could have been due to
misplacement of the femoral puncture (7). In the manual compression
group, such sins were much more easily masked when sheath pulling
took place at an activated clotting time (ACT) 150 s.
Fourth, prior published data have demonstrated that level of
anticoagulation, sheath size, physician learning curves, location of
puncture site, vessel size and presence of local atherosclerotic
disease all influence outcomes of vascular closure. The investigators
have demonstrated a mismatch in anticoagulation (ACT 277 vs.
150 s) and learning curves (experienced manual compression
technicians versus inexperienced closure device users). They do not
have the data regarding location of puncture site, atherosclerotic
disease or vessel size, and have failed to inform us regarding sheath
sizes other than that 10F sheath pulls were excluded. The latter
also raises the issue of possibly inappropriate use of closure devices
for larger than approved sheath sizes.
Fifth, Dangas and colleagues draw conclusions comparing two
sealing methods in a retrospective fashion using statistical methods
designed with the assumption that samples were selected at
random (8). Thus, the p values are misleading, adding to the
problems of this observational study with uncontrolled (retrospec-
tive) data acquisition, and ad hoc group assignment. These groups
are likely to have varied in ways the investigators did not notice or
chose to ignore, and these differences, rather than the treatment
modalities, may account for the potentially different outcomes.
Further, such studies can be subject to bias in completeness and
quality of information recorded in the hospital charts; the inves-
tigators reading such charts often must use considerable judgment
in assessing the data present. Sizing hematomas, for example, can
be difficult even in prospective studies and can be quite subjective
even with the most sophisticated measuring tools.
The study by Dangas et al. demonstrates that relatively novice
users of vascular closure devices, probably frequently not following
manufacturers’ recommendations, and deploying these devices in
fully anticoagulated patients, had a higher complication rate than
full-time employees trained to do manual compression who were
pulling sheaths when the ACT was 150 s. Perhaps the only truly
useful conclusion one could draw from the study (1) is that
operators should be well into their learning curve, should perform
an angiogram on the femoral artery before device deployment and
otherwise follow the recommended protocols before deployment in
fully anticoagulated patients. Although we use these devices after
percutaneous intervention in nearly 100% of our cases, we believe
that any recommendation should await the results of prospective
randomized studies applying uniform definitions of complications
and uniform measurement of end points.
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